Cargando…
Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent
PURPOSE: Ataxia telangiectasia mutated (ATM) is a key mediator of the DNA damage response, and several ATM inhibitors (ATMi) are currently undergoing early phase clinical trials for the treatment of cancer. A radiolabelled ATMi to determine drug pharmacokinetics could assist patient selection in a m...
Autores principales: | Fraser, Claudia Rose, Ajenjo, Javier, Veal, Mathew, Dias, Gemma Marie, Chan, Chung, O’Neill, Edward, Destro, Gianluca, Lau, Doreen, Pacelli, Anna, Gouverneur, Veronique, Hueting, Rebekka, Cornelissen, Bart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375819/ https://www.ncbi.nlm.nih.gov/pubmed/35962885 http://dx.doi.org/10.1186/s13550-022-00920-z |
Ejemplares similares
-
Imaging PARP with [(18)F]rucaparib in pancreatic cancer models
por: Chan, Chung Ying, et al.
Publicado: (2022) -
Closing the gap between (19)F and (18)F chemistry
por: Ajenjo, Javier, et al.
Publicado: (2021) -
Correction to: Closing the gap between (19)F and (18)F chemistry
por: Ajenjo, Javier, et al.
Publicado: (2022) -
[(123)I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer
por: Chan, Chung Ying, et al.
Publicado: (2023) -
Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [(18)F]olaparib in mouse models of glioma
por: Chan, Chung Ying, et al.
Publicado: (2022)